Cargando…

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients

Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by elevated pulmonary arterial pressure and organized thrombi within pulmonary arteries. Riociguat is a soluble guanylate cyclase stimulator and is approved for patients with inoperable CTEPH or residual pulmonary hypertension af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jujo Sanada, Takayuki, Manz, Xue D., Symersky, Petr, Pan, Xiaoke, Yoshida, Keimei, Aman, Jurjan, Bogaard, Harm Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768460/ https://www.ncbi.nlm.nih.gov/pubmed/36568694 http://dx.doi.org/10.1002/pul2.12146

Ejemplares similares

Tyrosine Kinases and Endothelial Homeostasis in Pulmonary Arterial Hypertension: Too Hot to Handle?
por: Bogaard, Harm Jan, et al.
Publicado: (2022)

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
por: Newnham, Michael, et al.
Publicado: (2019)

Pulmonary hypertension with warm hands
por: Botros, Liza, et al.
Publicado: (2017)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Dynamic vascular changes in chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy
por: Ruigrok, Dieuwertje, et al.
Publicado: (2020)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

Right Ventricular Function During Exercise After Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
por: Braams, Natalia J., et al.
Publicado: (2023)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Noninvasive follow-up strategy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
por: Ruigrok, Dieuwertje, et al.
Publicado: (2022)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: A case series
por: Weir, Nargues A., et al.
Publicado: (2018)

Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy
por: Donaldson, Sahai, et al.
Publicado: (2020)

Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis
por: Ying, Miaofa, et al.
Publicado: (2021)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Increased Arterial Stiffness in Chronic Thromboembolic Pulmonary Hypertension Was Improved with Riociguat and Balloon Pulmonary Angioplasty: A Case Report
por: Sato, Shuji, et al.
Publicado: (2021)

Altered TGFβ/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention
por: Sanada, Takayuki Jujo, et al.
Publicado: (2021)

Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
por: Naito, Akira, et al.
Publicado: (2014)

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015)

Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta‐analysis
por: Wang, Wuwan, et al.
Publicado: (2019)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension
por: Boon, Gudula J.A.M., et al.
Publicado: (2021)

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study
por: Kawakami, Takashi, et al.
Publicado: (2020)

A modified perfusion protocol for pulmonary endarterectomy in a patient with a hematologic malignancy treated with a tyrosine kinase inhibitor
por: Haumann, Renard G, et al.
Publicado: (2021)

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice
por: Michaličková, Danica, et al.
Publicado: (2020)

The Cellular Landscape of Chronic Thromboembolic Pulmonary Hypertension Revealed by Single-Cell Sequencing: Therapeutic Implications?
por: Quarck, Rozenn, et al.
Publicado: (2023)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension
por: Kenny, Marianne, et al.
Publicado: (2020)

Clinical characteristics and prognosis in patients with chronic thromboembolic pulmonary hypertension and a concomitant psychiatric disorder
por: Tajima, Hiroshi, et al.
Publicado: (2019)

Combination of rescue balloon pulmonary angioplasty and riociguat therapy for chronic thromboembolic pulmonary hypertension with nonsustained polymorphic ventricular tachycardia: A case report
por: Fukuda, Yoshitake, et al.
Publicado: (2023)

A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension
por: Smits, A. Josien, et al.
Publicado: (2022)

Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment
por: Yanagisawa, Asako, et al.
Publicado: (2021)

Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension
por: Naito, Akira, et al.
Publicado: (2019)

Nocturnal Hypoxemia and High Circulating TNF-α Levels in Chronic Thromboembolic Pulmonary Hypertension
por: Naito, Akira, et al.
Publicado: (2020)

Real-world experience with riociguat as potential bridging therapy in patients with chronic thromboembolic pulmonary hypertension: a case series
por: Balasubramanian, Vijay P., et al.
Publicado: (2020)

Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial
por: Zhao, Qin-Hua, et al.
Publicado: (2021)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qtl0s6t8p8hla7o6lr0oa5tgov